AR088018A1 - Proceso e intermediarios para preparar lapatinib - Google Patents

Proceso e intermediarios para preparar lapatinib

Info

Publication number
AR088018A1
AR088018A1 ARP110100993A ARP110100993A AR088018A1 AR 088018 A1 AR088018 A1 AR 088018A1 AR P110100993 A ARP110100993 A AR P110100993A AR P110100993 A ARP110100993 A AR P110100993A AR 088018 A1 AR088018 A1 AR 088018A1
Authority
AR
Argentina
Prior art keywords
lapatinib
intermediaries
prepare
pharmaceutically acceptable
ditosyl
Prior art date
Application number
ARP110100993A
Other languages
English (en)
Inventor
Chen Yung
Paul Fa-Henschke Julian
Chu Guodong
Zhang Xiaoheng
Liu Yuanlian
Original Assignee
Scinopharm Taiwan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Taiwan Ltd filed Critical Scinopharm Taiwan Ltd
Publication of AR088018A1 publication Critical patent/AR088018A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Un proceso para hacer lapatinib y sus sales farmacéuticamente aceptables utilizando intermediarios. También se provee un proceso para obtener una forma farmacéutica de ditosilalo de lapatinib como monohidrato. Reivindicación 1: Un proceso para preparar lapatinib y su sal farmacéuticamente aceptable, caracterizado porque comprende convertir un compuesto de fórmula (1) en lapatinib.
ARP110100993A 2010-03-23 2011-03-23 Proceso e intermediarios para preparar lapatinib AR088018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31642510P 2010-03-23 2010-03-23

Publications (1)

Publication Number Publication Date
AR088018A1 true AR088018A1 (es) 2014-05-07

Family

ID=44672462

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100993A AR088018A1 (es) 2010-03-23 2011-03-23 Proceso e intermediarios para preparar lapatinib

Country Status (13)

Country Link
US (1) US8563719B2 (es)
EP (1) EP2550269B1 (es)
JP (1) JP5833626B2 (es)
KR (1) KR101718578B1 (es)
CN (1) CN102812019B (es)
AR (1) AR088018A1 (es)
AU (1) AU2011232219B2 (es)
CA (1) CA2793742C (es)
ES (1) ES2576871T3 (es)
IL (1) IL222085A (es)
PT (1) PT2550269E (es)
TW (1) TWI453202B (es)
WO (1) WO2011116634A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916574B2 (en) 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
MX2013007257A (es) * 2010-12-23 2013-10-01 Apotex Pharmachem Inc Un proceso para la preparación de lapatinib y su sal ditosilato.
ITMI20110480A1 (it) * 2011-03-25 2012-09-26 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di lapatinib e suoi sali
CN102702116B (zh) * 2012-06-13 2014-12-31 华南理工大学 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
CN102702179A (zh) * 2012-06-13 2012-10-03 华南理工大学 4-(3-氯-4-甲氧基苯胺基)-6-(呋喃-2-基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
CN105732596B (zh) * 2012-11-19 2019-05-28 齐鲁制药有限公司 N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
CN103819461B (zh) * 2012-11-19 2016-06-15 齐鲁制药有限公司 N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
US9024023B2 (en) 2013-01-14 2015-05-05 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
CN103242302B (zh) * 2013-05-22 2015-08-05 苏州明锐医药科技有限公司 拉帕替尼的制备方法
CN104418845B (zh) * 2013-09-04 2017-08-25 神隆医药（常熟）有限公司 制备拉帕替尼的方法和中间体
CN104513231A (zh) * 2015-01-09 2015-04-15 安润医药科技（苏州）有限公司 拉帕替尼及其中间体的合成方法
EP3266773B1 (en) * 2016-07-04 2018-04-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of lapatinib ditosylate monohydrate by means of an improved crystallization procedure
CN106432206A (zh) * 2016-08-30 2017-02-22 成都美睿科生物科技有限公司 一种用于合成拉帕替尼或其中间体5‑(4‑羟基喹唑啉)‑呋喃‑2‑甲醛的方法
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
CN111153860B (zh) * 2019-12-30 2021-06-29 广州六顺生物科技股份有限公司 一种喹唑啉类化合物的晶型及其制备方法
CN113321642A (zh) * 2021-08-02 2021-08-31 北京鑫开元医药科技有限公司 一种喹唑啉类亚胺化合物及其应用和制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT912559E (pt) * 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU2005203303B2 (en) 2000-06-30 2008-04-24 Glaxo Group Limited Quinazoline ditosylate salt compounds
CZ299561B6 (cs) 2000-06-30 2008-09-03 Glaxo Group Limited Chinazolinaminový derivát a farmaceutický prostredek
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
ES2290743T3 (es) * 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
KR20070107004A (ko) 2004-12-17 2007-11-06 스미스클라인 비이참 (코르크) 리미티드 암 치료 방법
US7713978B2 (en) * 2006-03-31 2010-05-11 Nigel Paul King Compounds
US20090203718A1 (en) 2006-04-13 2009-08-13 Smithkline Beecham (Cork) Ltd. Cancer treatment method
WO2008009078A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2009006086A2 (en) * 2007-06-29 2009-01-08 Sanofi-Aventis A new process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl}-phenyl)- 2-methylpropionic acid
WO2009042613A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
WO2009079541A1 (en) 2007-12-18 2009-06-25 Smithkline Beecham (Cork) Limited Quinazoline ditosylate anhydrate forms
WO2010017387A2 (en) * 2008-08-06 2010-02-11 Teva Pharmaceutical Industries Ltd. Lapatinib intermediates

Also Published As

Publication number Publication date
AU2011232219A9 (en) 2015-09-24
JP2013522327A (ja) 2013-06-13
TWI453202B (zh) 2014-09-21
CN102812019A (zh) 2012-12-05
IL222085A (en) 2015-11-30
CN102812019B (zh) 2015-12-16
WO2011116634A1 (en) 2011-09-29
JP5833626B2 (ja) 2015-12-16
PT2550269E (pt) 2016-06-20
KR20130069552A (ko) 2013-06-26
ES2576871T3 (es) 2016-07-11
TW201141852A (en) 2011-12-01
US20130005971A1 (en) 2013-01-03
KR101718578B1 (ko) 2017-03-21
EP2550269B1 (en) 2016-03-23
AU2011232219A2 (en) 2013-01-31
CA2793742A1 (en) 2011-09-29
EP2550269A1 (en) 2013-01-30
AU2011232219B2 (en) 2016-02-04
US8563719B2 (en) 2013-10-22
AU2011232219A1 (en) 2012-10-18
EP2550269A4 (en) 2013-08-21
CA2793742C (en) 2015-06-23

Similar Documents

Publication Publication Date Title
AR088018A1 (es) Proceso e intermediarios para preparar lapatinib
AR084903A1 (es) Derivados de aminodihidrotiazina fusionada
CR20140237A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
MX2013015436A (es) Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos.
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2
CO6751286A2 (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
UY32499A (es) Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
EA201200498A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
EA201391206A1 (ru) Способы синтеза производных предшественника молибдоптерина z
EA201200123A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
UY32500A (es) Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
ECSP12012207A (es) Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida
CL2012001081A1 (es) Procesos de preparcion de compuestos intermediarios en la sintesis de valsartan por hidrolisis de un ester utilizando salesde aluminio.
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
EA201100230A1 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
UY34423A (es) Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
DOP2013000284A (es) Derivados de pirazol útiles como inhibidores de aldosterona sintasa
AR092627A1 (es) Derivados glucopiranosidos de urea
UY35561A (es) Procedimiento de síntesis del 3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7- carbonitrilo, y aplicación a la síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same

Legal Events

Date Code Title Description
FB Suspension of granting procedure